Item 7.01 Regulation FD Disclosure.
On June
6, 2017, ANI Pharmaceuticals, Inc. (the “Company,” “we” or “us”) posted to its website its
June 2017 Corporate Presentation. We may use this presentation in our communications or at conferences. The presentation is available
on our website, www.anipharmaceuticals.com, and is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated
into this Item 7.01 by reference.
In accordance
with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not
be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration
statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly
set forth by specific reference in such filing.
Forward-Looking Statements
Certain statements contained in the presentation slides furnished
with this report contain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future operations, products, financial
position, operating results, prospects, pipeline or potential markets therefor, and other statements that are not historical in
nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,”
“plans,” “potential,” “future,” “believes,” “intends,” “continue,”
other words of similar meaning, derivations of such words, and the use of future dates.
Uncertainties and risks may cause our actual results to be materially
different than those expressed in or implied by such forward-looking statements. Uncertainties and risks include, but are not limited
to, the risk that we may face with respect to importing raw materials, increased competition, acquisitions, contract manufacturing
arrangements, delays or failure in obtaining product approval from the U.S. Food and Drug Administration ("FDA"), general
business and economic conditions, market trends, product development, regulatory and other approvals and marketing.
More detailed information on these and additional
factors that could affect our actual results are described in our filings with the Securities and Exchange Commission, including
our most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as our proxy statement/prospectus, filed
with the Securities and Exchange Commission on April 6, 2017. The forward-looking statements contained in this document are made
only as of the date of this document. We undertake no obligation to update or revise any forward-looking statement, whether as
a result of new information, future events or otherwise.